Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mercanto HoldingsTGSHF 33 EV-to-EBITDA is 151.07 as of Aug. 02, 2026. GuruFocus rates TGSHF with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 746 Drug Manufacturers companies, Mercanto Holdings ranks worse than 97.05% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mercanto Holdings's enterprise value is $4.08 Mil.
Mercanto Holdings's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $0.03 Mil. Therefore, Mercanto Holdings's EV-to-EBITDA for today is 151.07.
The historical rank and industry rank for Mercanto Holdings's EV-to-EBITDA or its related term are showing as below:
TGSHF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -930.23 Med: -8.68 Max: 1481.85
Current: 173.42
During the past 5 years, the highest EV-to-EBITDA of Mercanto Holdings was 1481.85. The lowest was -930.23. And the median was -8.68.
TGSHF's EV-to-EBITDA is ranked worse than 97.05% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.995
vs TGSHF: 173.42
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mercanto Holdings's PE Ratio (TTM) for today is calculated as:
Mercanto Holdings's share price for today is $0.0033.
Mercanto Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Mercanto Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mercanto Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercanto Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercanto Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mercanto Holdings's EV-to-EBITDA falls into.
Mercanto Holdings's current Enterprise Value is $4.08 Mil.
Mercanto Holdings's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mercanto Holdings (TGSHF) has a EV-to-EBITDA of 151.07 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mercanto Holdings. According to the industry distribution chart, Mercanto Holdings ranks #724 out of 746 companies in the Drug Manufacturers industry, placing it in the top 97.1%.
Is Mercanto Holdings' EV-to-EBITDA too high?
Mercanto Holdings' current EV-to-EBITDA is 151.07. The Drug Manufacturers industry median EV-to-EBITDA is 13.00. Mercanto Holdings' value of 151.07 is 1062.5% above this industry median. Based on the distribution chart, Mercanto Holdings ranks #724 out of 746 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mercanto Holdings has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Mercanto Holdings' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mercanto Holdings ranks #724 out of 746 companies for EV-to-EBITDA. This places Mercanto Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. Mercanto Holdings' value of 151.07 is 1062.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.00, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mercanto Holdings's current EV-to-EBITDA of 151.07 is 1062.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mercanto Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercanto Holdings's current EV-to-EBITDA is 151.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercanto Holdings stock overvalued right now?
Mercanto Holdings (TGSHF) has a current EV-to-EBITDA of 151.07. The current EV-to-EBITDA is 151.07 and 1062.5% above the Drug Manufacturers industry median of 13.00. Mercanto Holdings' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Mercanto Holdings (TGSHF), the current EV-to-EBITDA is 151.07 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mercanto Holdings Inc operates a portfolio of brands that include traditional cannabis and beverage products. The company exists to promote the use of mushrooms through its brands; The company offers quality products that promote health, recreation, and well-being. The portfolio of the company includes different cannabis products, probiotic, functional mushroom beverages, and others.
33GF Score
Get the complete analysis for TGSHF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGSHF has been successfully added to your 
